Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Other

PharmAla To Supply Amsterdam UMC with LaNeo(TM) MDMA, Including Development of New Single-Capsule Stability Data

By The Northwire Desk — AI Analysis Feb 23, 2026 · 08:30 MDMA · 0.1 Pharmala Biotech Holdings Inc.
MDMA · Price

Executive Summary

  • PharmAla Biotech Holdings Inc. has executed a binding supply agreement with Amsterdam University Medical Center (Amsterdam UMC) to provide LaNeo™ 40 mg MDMD capsules for a proposed clinical trial.
  • The contract includes a three‑year stability‑testing program for the single‑capsule dosage form, data that will be used to develop commercial‑grade blister packaging—critical for future commercialization.
  • Delivery is contingent on a Quality Agreement and customary regulatory approvals; the agreement expands PharmAla’s European clinical footprint and supports its broader commercial strategy.

Key Details

  • Parties: PharmAla Biotech Holdings Inc. (CSE: MDMA / OTCQB: MDXXF) and Amsterdam University Medical Center, Netherlands.
  • Product Supplied: LaNeo™ 40 mg MDMA capsules, repackaged in a new single‑capsule format.
  • Stability Program: Three‑year testing of the single‑capsule dosage to generate stability data for future blister packaging development.
  • Commercial Implication: Stability data is a prerequisite for commercial‑grade blister packs, the industry standard for pharmaceutical distribution, enabling more efficient global trial and commercial supply.
  • Conditional Elements: Execution of a Quality Agreement with Amsterdam UMC’s Clinical Pharmacy; delivery subject to regulatory approvals and direction from Amsterdam UMC.
  • Strategic Impact: Enhances PharmAla’s European value chain, supports researchers across the continent, and moves the company toward a “truly commercial‑grade product.”

Notable Quotes

“We are delighted to be working with Amsterdam UMC, one of Europe’s leading academic medical centres… the stability testing program … will generate single‑capsule stability data that we intend to use as the foundation for developing blister packaging for LaNeo™ MDMA. This is an important step towards a truly commercial‑grade product.” – Nicholas Kadysh, CEO, PharmAla Biotech Holdings Inc.

Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property May 13, 2026 · 08:30

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations